Genetic predisposition to drug-induced hepatotoxicity

https://doi.org/10.1016/S0168-8278(97)80492-8Get rights and content

Abstract

Drug-induced hepatitis is uncommon and generally unpredictable. Hepatotoxicity may be related to the drug itself, or to chemically reactive metabolites which can bind covalently to hepatic macromolecules and may lead to either idiosyncratic, toxic hepatitis or to immunoallergic hepatitis. There is now evidence indicating that genetic variations in systems of biotransformation or detoxication may modulate either the toxic or sensitizing effects of some drugs. Thus, the genetic deficiency in a particular hepatic cytochrome P 450 isozyme (CYP 2D6) is involved in perhexiline liver injury. The deficiency in CYP 2C19 might also contribute to Atrium hepatotoxicity. Slow acetylation related to N-acetyltransferase 2 deficiency contributes to sulfonamide hepatitis. The genetic deficiency in glutathione synthetase may increase the susceptibility to several drugs including acetaminophen. A constitutional deficiency in another cell defense mechanism, still not characterized, seems to increase significantly the risk of hepatotoxicity with halothane, phenytoin, carbamazepine, phenobarbital, sulfamides and amineptine.

References (74)

  • AE Cribb et al.

    Role of polymorphic and monomorphic human arylamine N-acetyl-transferases in determining sulfamethoxazole metabolism

    Biochem Pharmacol

    (1993)
  • D Hickman et al.

    N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans

    Biochem Pharmacol

    (1991)
  • SC Mitchell et al.

    The deficiency of sulphoxidation of S-carboxymethylcysteine

    Pharmacol Ther

    (1989)
  • PG Richman et al.

    Regulation of gamma-glutamyl-cysteine synthetase by nonallosteric feedback inhibition by glutathione

    J Biol Chem

    (1975)
  • MA Gennis et al.

    Familial occurrence of hypersensitivity to phenytoin

    Am J Med

    (1991)
  • J Genève et al.

    Metabolic activation of the tricyclic antidepressant amineptine. I. Cytochrome P-450-mediated in vitro covalent binding

    Biochem Pharmacol

    (1987)
  • J Genève et al.

    Metabolic activation of the tricyclic antidepressant amineptine. II. Protective role of glutathione against in vitro and in vivo covalent binding

    Biochem Pharmacol

    (1987)
  • J Genève et al.

    Metabolic activation of the tricyclic antidepressant amineptine by human liver cytochrome P-450

    Biochem Pharmacol

    (1987)
  • A Berson et al.

    Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis

    J Hepatol

    (1994)
  • BHCH Stricker
    (1992)
  • GC Farrell
    (1994)
  • D Pessayre

    Mécanisme des hépatites médicamenteuses. Une conséquence de la superposition de deux systèmes xénophobes

    Gastroenterol Clin Biol

    (1995)
  • D Pessayre et al.
  • JP Miguet et al.

    Jaundice from troleandomycin and oral contraceptives

    Ann Intern Med

    (1980)
  • D Fisher et al.

    Inhibition of rat liver estrogen 2/4-hydroxylase activity by troleandomycin: comparison with erythromycin and roxithromycin

    J Pharmacol Exp Ther

    (1990)
  • D Larrey et al.

    Effects of pregnancy on the toxicity and metabolism of acetaminophen in mice

    J Pharmacol Exp Ther

    (1986)
  • SP Spielberg

    In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans

    Fed Proc

    (1984)
  • FJ Gonzalez et al.

    Pharmacogenetic phenotyping and genotyping. Present status and future potential

    Clin Pharmacokinet

    (1994)
  • DR Nelson et al.

    The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature

    DNA Cell Biol

    (1993)
  • A Maghoub et al.

    Polymorphic hydroxylation of debrisoquine in man

    Lancet

    (1977)
  • D Larrey et al.

    Polymorphism of dextromethorphan oxidation in a French population

    Br J Clin Pharmacol

    (1987)
  • G Alvan et al.

    Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

    Eur J Clin Pharmacol

    (1990)
  • K Brosen et al.

    Clinical significance of the sparteine/debrisoquine oxidation polymorphism

    Eur J Clin Pharmacol

    (1989)
  • MY Morgan et al.

    Impaired oxidation of debrisoquine in patients perhexiline liver injury

    Gut

    (1984)
  • D Larrey et al.

    Effect of liver diseases on dextromethorphan oxidation capacity and phenotype. Study in 107 patients

    Br J Clin Pharmacol

    (1989)
  • RR Shah et al.

    Impaired oxidation of debrisoquine in patients with perhexiline neuropathy

    Br Med J

    (1982)
  • D Larrey et al.

    Genetic predisposition to drug hepatotoxicity. Role in hepatitis caused by amineptine, a tricyclic antidepressant

    Hepatology

    (1989)
  • Cited by (94)

    • Pharmacogenomics, concepts for the future of perioperative medicine and pain management: A review

      2020, Best Practice and Research: Clinical Anaesthesiology
      Citation Excerpt :

      While MH is related to a specific functional mechanism in a calcium channel, halothane-induced hepatitis results from an immune response to metabolites produced by the cytochrome enzyme CYP2E1. This occurs in approximately 1 in 10,000 patients, and although the genetic mechanisms involved are not entirely clear, there is clear evidence that it is familial [34–36]. Physiological responses to inhalation anesthetics vary; however, genetic mutations often only affect these responses at anesthetic concentrations much higher than those usually used in mammals.

    • Hepatotoxicity of Dermatologic Drug Therapy

      2020, Comprehensive Dermatologic Drug Therapy, Fourth Edition
    • Glutathione metabolism modeling: A mechanism for liver drug-robustness and a new biomarker strategy

      2013, Biochimica et Biophysica Acta - General Subjects
      Citation Excerpt :

      This is illustrated by the observed association between polymorphisms in GCS, tissue glutathione concentrations and disease susceptibility in the human population [17–19]. However, it is important to note that other studies have identified only a limited correlation between liver injury and genetic polymorphisms in other enzymes of the glutathione pathway, or numerous drug metabolizing enzymes, and susceptibility to adverse drug reactions [20,21]. This could be due to a lack of influence of the affected enzymes on hepatic glutathione concentrations [22] or the complexity of the underlying mechanisms, which include many non-genetic factors [23].

    • Hepatotoxicity of dermatologic drug therapy

      2012, Comprehensive Dermatologic Drug Therapy: Expert Consult - Online and Print
    View all citing articles on Scopus
    View full text